{"id":859292,"date":"2025-06-10T16:51:46","date_gmt":"2025-06-10T20:51:46","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxart-to-host-conference-call-on-june-11-at-830-am-et-to-discuss-topline-results-from-its-phase-i-norovirus-trial\/"},"modified":"2025-06-10T16:51:46","modified_gmt":"2025-06-10T20:51:46","slug":"vaxart-to-host-conference-call-on-june-11-at-830-am-et-to-discuss-topline-results-from-its-phase-i-norovirus-trial","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxart-to-host-conference-call-on-june-11-at-830-am-et-to-discuss-topline-results-from-its-phase-i-norovirus-trial\/","title":{"rendered":"Vaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus Trial"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">SOUTH SAN FRANCISCO, Calif., June  10, 2025  (GLOBE NEWSWIRE) &#8212; Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced it will release topline data from the norovirus Phase I trial before the market open on Wednesday, June 11, 2025. The Vaxart senior management team will host a live conference call on the same date beginning at 8:30 a.m. Eastern Time to review the data and provide a trial update.<\/p>\n<p>The conference call can be accessed using the following information:<\/p>\n<p>Webcast:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0nyv83uXu2xqfuhzIMsIY2S-98I9Nt46RApC9TXC38PhGQh4EGgnFHxTqkSwCkvSZP9hVWmqPNWdJuEm0ZQ-ZNe33zE5Kij3W9K8Ua6b_tqfb2C8V-Sn4lv1BXeRRv7CWy7DbagqGDVCd0Vx5gzttfJNEjFWvfzfQ0ViSKml4RMPwF6Ee0NiKBWmCxXv3cN1EwMm5D0o9WcJVfJNrR42RJJzU7BGspuBEFTXb2vHtHbRta-BDFvrFyBZaa36T5eS1OBdn_PpCTVE_Ua9LHtm_ozmOzReBTorQ2-Wd_oO7m3rRwkFYnGxxIJP0QyVKzj5u_t-D00hZZsdB82-ryrowG_n0ZG_Ng64zKqi-Dq3-vY=\" rel=\"nofollow\" target=\"_blank\"><u>Click here<\/u><\/a><br \/>Date:\u00a0Wednesday, June 11, 2025\u00a0\u2013\u00a08:30 a.m. ET<br \/>Domestic: (877) 407-0832<br \/>International: (201) 689-8433<br \/>Conference ID: 13754315<\/p>\n<p align=\"justify\">Investors may submit written questions in advance of the conference call to <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=1qCGMvuERXWcKHViEdHyGasluXayGmuVtbjs8YkqCpIfa0Jwno7NO-OykjVeErjn3pyRf5BM2lKsPR52FRawJQ==\" rel=\"nofollow\" target=\"_blank\">ir@vaxart.com<\/a>.<\/p>\n<p align=\"justify\">A replay of the webcast will be available on the Company\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9d4tUcyVCSAvsrK4JV6B5q44Cg2fDzF3gQUf-74Rcn7zF_htE9DmqRKL8Roffeqhim2kUK1WlrjVbYPXam2w3g==\" rel=\"nofollow\" target=\"_blank\">www.vaxart.com<\/a> following the conclusion of the event.<\/p>\n<p align=\"justify\">\n        <strong>About Vaxart<\/strong><br \/>\n        <br \/>Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart\u2019s development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart\u2019s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.<\/p>\n<p>\n        <strong>Contact<\/strong>\n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"vertical-align: top\">\n            <strong>Vaxart\u00a0Media and Investor Relations:<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">Matt Steinberg<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">FINN Partners<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">\n            <a href=\"mailto:IR@vaxart.com\" rel=\"nofollow\" target=\"_blank\">IR@vaxart.com<\/a>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">(646) 871-8481<\/td>\n<\/tr>\n<\/table>\n<p>This press release was published by a CLEAR\u00ae Verified individual.<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2NjU4OCM2OTg1MDE5IzIwMTkxMDk=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MWU2OWJkZDctOTZlNy00MmEzLWI0YjctZTFkMzQyYTU4MWQwLTEwMzA2ODItMjAyNS0wNi0xMC1lbg==\/tiny\/Vaxart-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SOUTH SAN FRANCISCO, Calif., June 10, 2025 (GLOBE NEWSWIRE) &#8212; Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced it will release topline data from the norovirus Phase I trial before the market open on Wednesday, June 11, 2025. The Vaxart senior management team will host a live conference call on the same date beginning at 8:30 a.m. Eastern Time to review the data and provide a trial update. The conference call can be accessed using the following information: Webcast:\u00a0Click hereDate:\u00a0Wednesday, June 11, 2025\u00a0\u2013\u00a08:30 a.m. ETDomestic: (877) 407-0832International: (201) 689-8433Conference ID: 13754315 Investors may submit written questions in advance of the conference call to ir@vaxart.com. &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/vaxart-to-host-conference-call-on-june-11-at-830-am-et-to-discuss-topline-results-from-its-phase-i-norovirus-trial\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Vaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus Trial&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-859292","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Vaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus Trial - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/vaxart-to-host-conference-call-on-june-11-at-830-am-et-to-discuss-topline-results-from-its-phase-i-norovirus-trial\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Vaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus Trial - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SOUTH SAN FRANCISCO, Calif., June 10, 2025 (GLOBE NEWSWIRE) &#8212; Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced it will release topline data from the norovirus Phase I trial before the market open on Wednesday, June 11, 2025. The Vaxart senior management team will host a live conference call on the same date beginning at 8:30 a.m. Eastern Time to review the data and provide a trial update. The conference call can be accessed using the following information: Webcast:\u00a0Click hereDate:\u00a0Wednesday, June 11, 2025\u00a0\u2013\u00a08:30 a.m. ETDomestic: (877) 407-0832International: (201) 689-8433Conference ID: 13754315 Investors may submit written questions in advance of the conference call to ir@vaxart.com. &hellip; Continue reading &quot;Vaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus Trial&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/vaxart-to-host-conference-call-on-june-11-at-830-am-et-to-discuss-topline-results-from-its-phase-i-norovirus-trial\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-10T20:51:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2NjU4OCM2OTg1MDE5IzIwMTkxMDk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxart-to-host-conference-call-on-june-11-at-830-am-et-to-discuss-topline-results-from-its-phase-i-norovirus-trial\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxart-to-host-conference-call-on-june-11-at-830-am-et-to-discuss-topline-results-from-its-phase-i-norovirus-trial\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Vaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus Trial\",\"datePublished\":\"2025-06-10T20:51:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxart-to-host-conference-call-on-june-11-at-830-am-et-to-discuss-topline-results-from-its-phase-i-norovirus-trial\\\/\"},\"wordCount\":319,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxart-to-host-conference-call-on-june-11-at-830-am-et-to-discuss-topline-results-from-its-phase-i-norovirus-trial\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ2NjU4OCM2OTg1MDE5IzIwMTkxMDk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxart-to-host-conference-call-on-june-11-at-830-am-et-to-discuss-topline-results-from-its-phase-i-norovirus-trial\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxart-to-host-conference-call-on-june-11-at-830-am-et-to-discuss-topline-results-from-its-phase-i-norovirus-trial\\\/\",\"name\":\"Vaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus Trial - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxart-to-host-conference-call-on-june-11-at-830-am-et-to-discuss-topline-results-from-its-phase-i-norovirus-trial\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxart-to-host-conference-call-on-june-11-at-830-am-et-to-discuss-topline-results-from-its-phase-i-norovirus-trial\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ2NjU4OCM2OTg1MDE5IzIwMTkxMDk=\",\"datePublished\":\"2025-06-10T20:51:46+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxart-to-host-conference-call-on-june-11-at-830-am-et-to-discuss-topline-results-from-its-phase-i-norovirus-trial\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxart-to-host-conference-call-on-june-11-at-830-am-et-to-discuss-topline-results-from-its-phase-i-norovirus-trial\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxart-to-host-conference-call-on-june-11-at-830-am-et-to-discuss-topline-results-from-its-phase-i-norovirus-trial\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ2NjU4OCM2OTg1MDE5IzIwMTkxMDk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ2NjU4OCM2OTg1MDE5IzIwMTkxMDk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxart-to-host-conference-call-on-june-11-at-830-am-et-to-discuss-topline-results-from-its-phase-i-norovirus-trial\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Vaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Vaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus Trial - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxart-to-host-conference-call-on-june-11-at-830-am-et-to-discuss-topline-results-from-its-phase-i-norovirus-trial\/","og_locale":"en_US","og_type":"article","og_title":"Vaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus Trial - Market Newsdesk","og_description":"SOUTH SAN FRANCISCO, Calif., June 10, 2025 (GLOBE NEWSWIRE) &#8212; Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced it will release topline data from the norovirus Phase I trial before the market open on Wednesday, June 11, 2025. The Vaxart senior management team will host a live conference call on the same date beginning at 8:30 a.m. Eastern Time to review the data and provide a trial update. The conference call can be accessed using the following information: Webcast:\u00a0Click hereDate:\u00a0Wednesday, June 11, 2025\u00a0\u2013\u00a08:30 a.m. ETDomestic: (877) 407-0832International: (201) 689-8433Conference ID: 13754315 Investors may submit written questions in advance of the conference call to ir@vaxart.com. &hellip; Continue reading \"Vaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus Trial\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxart-to-host-conference-call-on-june-11-at-830-am-et-to-discuss-topline-results-from-its-phase-i-norovirus-trial\/","og_site_name":"Market Newsdesk","article_published_time":"2025-06-10T20:51:46+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2NjU4OCM2OTg1MDE5IzIwMTkxMDk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxart-to-host-conference-call-on-june-11-at-830-am-et-to-discuss-topline-results-from-its-phase-i-norovirus-trial\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxart-to-host-conference-call-on-june-11-at-830-am-et-to-discuss-topline-results-from-its-phase-i-norovirus-trial\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Vaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus Trial","datePublished":"2025-06-10T20:51:46+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxart-to-host-conference-call-on-june-11-at-830-am-et-to-discuss-topline-results-from-its-phase-i-norovirus-trial\/"},"wordCount":319,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxart-to-host-conference-call-on-june-11-at-830-am-et-to-discuss-topline-results-from-its-phase-i-norovirus-trial\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2NjU4OCM2OTg1MDE5IzIwMTkxMDk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxart-to-host-conference-call-on-june-11-at-830-am-et-to-discuss-topline-results-from-its-phase-i-norovirus-trial\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxart-to-host-conference-call-on-june-11-at-830-am-et-to-discuss-topline-results-from-its-phase-i-norovirus-trial\/","name":"Vaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus Trial - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxart-to-host-conference-call-on-june-11-at-830-am-et-to-discuss-topline-results-from-its-phase-i-norovirus-trial\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxart-to-host-conference-call-on-june-11-at-830-am-et-to-discuss-topline-results-from-its-phase-i-norovirus-trial\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2NjU4OCM2OTg1MDE5IzIwMTkxMDk=","datePublished":"2025-06-10T20:51:46+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxart-to-host-conference-call-on-june-11-at-830-am-et-to-discuss-topline-results-from-its-phase-i-norovirus-trial\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/vaxart-to-host-conference-call-on-june-11-at-830-am-et-to-discuss-topline-results-from-its-phase-i-norovirus-trial\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxart-to-host-conference-call-on-june-11-at-830-am-et-to-discuss-topline-results-from-its-phase-i-norovirus-trial\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2NjU4OCM2OTg1MDE5IzIwMTkxMDk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2NjU4OCM2OTg1MDE5IzIwMTkxMDk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxart-to-host-conference-call-on-june-11-at-830-am-et-to-discuss-topline-results-from-its-phase-i-norovirus-trial\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Vaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus Trial"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/859292","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=859292"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/859292\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=859292"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=859292"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=859292"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}